您好, 访客   登录/注册
  •  > 中国论文网 > 
  • 医学论文  > 
  • 依托孕烯植入剂与左炔诺孕酮宫内缓释系统治疗子宫腺肌病的临床效果

依托孕烯植入剂与左炔诺孕酮宫内缓释系统治疗子宫腺肌病的临床效果

来源:用户上传      作者:林益琴 潘珊

  [摘要] 目的 探左炔孕酮宫内缓释系统和依托孕烯植入剂的非避孕益处。 方法 选择2018年2月至2019年7月间浙江省嘉兴市妇幼保健院收治的子宫腺肌病患者80例为研究对象,根据随机数字法将其分为两组,每组各40例,其中对照组给予左炔诺孕酮宫内缓释系统(曼月乐环)治疗,观察组则运用依托孕烯植入剂,对两组的治疗效果进行比较。 结果 治疗前,两组各项指标比较,差异无统计学意义(P>0.05);治疗后3、6、12、24个月,观察组的子宫体积均小于对照组(P<0.05);观察组的不痛比例为87.50%,高于对照组的75.00%(P<0.05);观察组的轻度、中度、重度疼痛比例为7.50%、5.00%、0,与对照组的12.50%、10.00%、2.50%比较,差异无统计学意义(P>0.05);观察组治疗后3、6、12、24个月的月经量均少于对照组(P<0.05);与对照组比较,观察组治疗后3、6、12、24个月的血红蛋白和血清CA125水平均较高,组间比较,差异有统计学意义(P<0.05);同时,两组的性激素水平比较,差异有统计学意义(P<0.05),但两组的不良反应发生率比较,差异无统计学意义(P>0.05)。 结论 与左炔诺孕酮宫内缓释系统相比,依托孕烯植入剂治疗子宫腺肌病不仅可改善痛经状况,提高治疗效果,且不易发生不良反应,具有较高的安全性,值得推广。
  [关键词] 子宫腺肌病;左炔诺孕酮宫内缓释系统;依托孕烯植入剂;性激素
  [中图分类号] R711 [文献标识码] B [文章编号] 1673-9701(2022)13-0055-04
  [Abstract] Objective To explore the non-contraceptive benefits of levonorgestrel-releasing intrauterine system and etonogestrel implants. Methods A total of 80 patients with adenomyosis admitted to Jiaxing Maternal and Child Health Hospital in Zhejiang Province from February 2018 to July 2019 were selected as the study objects and divided into two groups according to the number random method, with 40 cases in each group. The control group was given the levonorgestrel-releasing intrauterine system (Mirena),while the observation group was given etonogestrel implants. The treatment effects were compared and analyzed between the two groups. Results Before treatment, there were no differences in various indicators between the two groups(P>0.05).3,6,12 and 24 months after treatment, the uterine volume of the observation group was smaller than that of the control group(P<0.05).The pain free proportion in the observation group (87.50%) was higher than (75.00%) in the control group(P<0.05). However, there were no differences in the proportions of mild, moderate,and severe pain between the observation group(7.50%,5.00%,0) and the control group(12.50%,10.00%,2.50%)(P>0.05).The volume of menstruum of the observation group was less than that of the control group at 3, 6, 12, and 24 months after treatment(P<0.05). The levels of hemoglobin and serum CA125 in the observation group were higher than those in the control group at 3,6,12 and 24 months after treatment, with significant differences(P<0.05).At the same time, there was statistically significant difference in the sex hormone level between the two groups (P<0.05), but there was no difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Compared with the levonorgestrel-releasing intrauterine system, etonogestrel implants in the treatment of adenomyosis not only improves dysmenorrhea and treatment effect, but also is less prone to develop adverse reactions.It is of higher safety and worth promoting.

nlc202206161030



转载注明来源:https://www.xzbu.com/6/view-15433748.htm

相关文章

服务推荐